# IMpower151 (NCT04194203)

> A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

No report yet. It can be ordered.

- Drugs tested: atezolizumab plus bevacizumab
- Indication: chemotherapy-naïve stage IV non-squamous non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04194203
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Atezolizumab; Placebo; Bevacizumab; Paclitaxel; Pemetrexed; Carboplatin
- Enrollment: 305
- Primary outcome: Progression Free Survival (PFS) in the intent to treat (ITT) population, as determined by the investigator

## Indexed commentary on IMpower151 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=impower151-nct04194203

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04194203", "email": "<work email>"}; the inbox owner confirms by the emailed link.